COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067

被引：0
|
作者：
Baker, T. [1 ]
Paly, V. F. [1 ]
Johnson, H. M. [2 ]
Van Campenhout, H. [3 ]
Amadi, A. [2 ]
Chandran, N. [4 ]
Moshyk, A. [5 ]
Kotapati, S. [5 ]
机构：
[1] ICON Plc, New York, NY USA
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Braine Lalleud, Belgium
[4] ICON Plc, Bangalore, Karnataka, India
[5] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN142
引用
收藏
页码：S462 / S463
页数：2
相关论文
共 50 条
  • [31] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Xiuting Mo
    Kensuke Moriwaki
    Kosuke Morimoto
    Kojiro Shimozuma
    Clinical Drug Investigation, 2022, 42 : 599 - 609
  • [32] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Mo, Xiuting
    Moriwaki, Kensuke
    Morimoto, Kosuke
    Shimozuma, Kojiro
    CLINICAL DRUG INVESTIGATION, 2022, 42 (07) : 599 - 609
  • [33] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE
    Branchoux, S.
    Negrier, S.
    de Peretti, C.
    Malcolm, B.
    May, J.
    Marie, L.
    Gaudin, A. F.
    Klijn, S.
    Ignacio, T. J.
    VALUE IN HEALTH, 2019, 22 : S477 - S477
  • [34] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
    Yang, Liu
    Cao, Xueqiong
    Li, Na
    Zheng, Bin
    Liu, Maobai
    Cai, Hongfu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [35] Survival of responders to nivolumab (NIVO) plus ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
    Brahmer, J. R.
    Ciuleanu, T-E.
    Schenker, M.
    Audigier-Valette, C.
    Zurawski, B.
    Linardou, H.
    Kim, S-W.
    Otterson, G. A.
    Salman, P.
    De La Mora Jimenez, E.
    Lesniewski-Kmak, K.
    Ahmed, S.
    Albert, I.
    Barlesi, F.
    Feeney, K.
    Frickhofen, N.
    Li, A.
    Sun, P.
    Hellmann, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1445
  • [36] Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: A network meta-analysis
    Mohr, P.
    Toor, K.
    Goring, S.
    Chan, K.
    Besada, M.
    Johnson, H. M.
    Moshyk, A.
    Kotapati, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
    Ye, Zhuo-miao
    Tang, Zi-Qing
    Xu, Zhe
    Zhou, Qin
    Li, Huan
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [38] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA (UMPM) IN THE NETHERLANDS
    Daumont, M. J.
    Torkilseng, E.
    Pompen, M.
    Stevanovic, J.
    Stawowczyk, E.
    VALUE IN HEALTH, 2022, 25 (12) : S113 - S113
  • [39] Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
    Watson, Tina R.
    Gao, Xin
    Reynolds, Kerry L.
    Kong, Chung Yin
    JAMA NETWORK OPEN, 2020, 3 (10)
  • [40] Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
    Hao, Xuezhi
    Shen, Aizong
    Wu, Bin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345